Clarinaze® Allergy Control 0.05% nasal spray
Clarinaze® Allergy Control 0.05% nasal spray (0.05% mometasone furoate). Indications: Symptoms of seasonal or perennial allergic rhinitis in Adults aged ≥18 years. Dosage and Administration: Two actuations (50mcg/actuation) in each nostril once daily (total dose 200 mcg). Once symptoms are controlled, dose reduction to one actuation in each nostril (total dose 100 mcg). Product requires initial priming prior to first use. Contraindications: Hypersensitivity to any of the ingredients, presence of untreated localised infection of the nasal mucosa (e.g. herpes simplex), recent nasal surgery or trauma where healing has not yet occurred. Warnings and Precautions: Treatment should be stopped and medical advice sought if no improvement is seen in 14 days. Do not use for >3 months without consulting a doctor. Use with caution in patients with: active or quiescent tuberculosis, untreated fungal, bacterial, or systemic viral infections. Potentially immunosuppressed patients receiving corticosteroids should be warned of risk of infections (e.g., chickenpox, measles) and of the importance of obtaining medical advice if such exposure occurs. Patients on treatment over several months should be examined periodically for changes in nasal mucosa. Product contains benzalkonium chloride which may cause irritation or swelling inside the nose. Treatment is not recommended in patients with nasal septum perforation. Systemic effects of nasal corticosteroids may occur. Instances of increased intraocular pressure have been reported. Patients transferred from long- term administration of systemically active corticosteroids require careful attention. Side Effects: Epistaxis, Pharyngitis, Upper respiratory tract infection, Headache, Nasal burning, Nasal irritation, Nasal ulceration, Throat irritation. Pregnancy: No or limited data are available, treatment not recommended unless potential benefit to mother justifies potential risk. Cost: £7.69 – 140 actuations. MA Number: PL 00010/0663 MA Holder: Bayer plc, 400 South Oak Way, Reading, RG2 6AD, UK. Legal Category: P. Date of Preparation: October 2018.
® Registered trademark of Bayer